8 completed. 8 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 8 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow Vascular Fistula: new trials by email Literature Review of Vascular Fistula trials Research Report on Vascular Fistula
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access Vorapaxar sulfate, Placebo - AV Fistula | Phase 2 | Completed | Ken Mahaffey | 17 | 2015-08-26 | 2019-01-14 |
| An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access SRM003, Participating Site's standard practice - Arteriovenous Fistula | Phase 2 | Completed | Shire | 64 | 2013-03-26 | 2021-06-08 |
| Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula Rosuvastatin - End-stage Kidney Disease, Diabetes Mellitus | Phase 2 | Completed | National Cheng-Kung University Hospital | 60 | 2012-11-01 | 2019-02-19 |
| Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae Venous Window Needle Guide - End Stage Renal Disease, AV Fistula | Phase 2 / Phase 3 | Completed | Vital Access Corp. | 54 | 2011-12-01 | 2016-06-03 |
| A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease PRT-201, Placebo - Chronic Kidney Disease | Phase 2 | Completed | Proteon Therapeutics | 151 | 2011-03-01 | 2015-04-30 |
| A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients PRT-201 - Chronic Kidney Disease | Phase 1 / Phase 2 | Completed | Proteon Therapeutics | 66 | 2008-11-01 | 2015-04-30 |
| Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use Vascugel, Placebo Comparator - Hemodialysis Access | Phase 1 / Phase 2 | Completed | Pervasis Therapeutics, Inc | 65 | 2006-07-01 | 2011-10-27 |
| A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures. AQUAVAN® (fospropofol disodium) Injection - Procedural Sedation | Phase 2 / Phase 3 | Completed | Eisai Inc. | 123 | 2006-05-01 | 2012-06-20 |
Arteriovenous Fistula (8) · Kidney Failure, Chronic (3) · Fistula (2) · Renal Insufficiency, Chronic (2) · Bunion (1) · Diabetes Mellitus (1) · Dilatation, Pathologic (1) · Renal Insufficiency (1) · Vascular System Injuries (1)
Arteriovenous Malformations (8) · Cardiovascular Abnormalities (8) · Cardiovascular Diseases (8) · Congenital Abnormalities (8) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Pathological Conditions, Anatomical (8) · Pathological Conditions, Signs and Symptoms (8) · Vascular Diseases (8) · Vascular Malformations (8) · Fistula (6) · Chronic Disease (5) · Disease Attributes (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5)
cholesterol-binding protein (2) · Gelatin Sponge, Absorbable (1) · Injections (1) · Rosuvastatin Calcium (1) · fospropofol (1) · vorapaxar (1)
Proteon Therapeutics (2) · Eisai Inc. (1) · Ken Mahaffey (1) · National Cheng-Kung University Hospital (1) · Pervasis Therapeutics, Inc (1) · Shire (1) · Vital Access Corp. (1)
United States (7) · Taiwan (1)
James B Jones, MD, PharmD (1) · Jun-Neng Roan, MD, PhD (1) · Kenneth W Mahaffey, MD (1) · Mark Crawford, BA (1) · Matthew W Mell, MD, MS (1)